openPR Logo
Press release

Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023 | GemVax & Kael, Health Ever Bio-Tech Co., Ltd, Nymox Corporation

02-14-2023 01:02 PM CET | Health & Medicine

Press release from: Global Insight Services

Benign Prostatic Hyperplasia - Drug Pipeline

Benign Prostatic Hyperplasia - Drug Pipeline

Benign Prostatic Hyperplasia (BPH) also called as prostate gland enlargement, is a noncancerous increase in size of the prostate gland. An enlarged prostate gland can cause uncomfortable urinary symptoms, such as blocking the flow of urine out of the bladder.

To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31218

The common causes of BPH include changes in male sex hormones, any family history of prostate problems or any abnormalities with testicles risk of BPH. Symptoms include incomplete bladder emptying, leakage of urine, obstructing the flow of urine, frequent or urgent need to urinate, increased frequency of urination at night (nocturia), difficulty starting urination, dribbling at the end of urination.

Diagnosis of BPH involves a physical exam and medical history. The physical exam includes a rectal examination to estimate the size and shape of prostate. Diagnostic tests include Urodynamic test, prostate-specific antigen (PSA) test, post-void residual and cystoscopy. The most common treatments for Benign Prostatic Hyperplasia are medications, minimally invasive therapies and surgery.

Read more about Benign Prostatic Hyperplasia - Drug Pipeline here: https://www.globalinsightservices.com/reports/benign-prostatic-hyperplasia-drug-pipeline-landscape/

Report Highlights
Global Insight Service's, Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023 report provides an overview of the Benign Prostatic Hyperplasia pipeline drugs. This report covers detailed insights on Benign Prostatic Hyperplasia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Benign Prostatic Hyperplasia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS31218

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Benign Prostatic Hyperplasia treatment such as MCS-2, Fexapotide Triflutate, GV1001 and others. Key players involved in the development of therapies to treat benign prostatic hyperplasia are GemVax & Kael, Health Ever Bio-Tech Co., Ltd, Nymox Corporation, Dongkook Pharmaceutical Co., Ltd, Urovant Sciences GmbH and others. Two drugs are under late-stage Pre-registration, three drugs are under Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Preclinical and Discovery stages of development.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31218

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023 | GemVax & Kael, Health Ever Bio-Tech Co., Ltd, Nymox Corporation here

News-ID: 2929467 • Views:

More Releases from Global Insight Services

Governance Risk and Compliance (GRC) Platform Market to Expand From $53.5 Billion in 2024 to $152 Billion by 2034 With 11% CAGR
Governance Risk and Compliance (GRC) Platform Market to Expand From $53.5 Billio …
The Governance Risk And Compliance (GRC) Platform Market has emerged as a cornerstone for organizations striving to enhance accountability, streamline risk management, and meet growing regulatory demands. GRC platforms provide an integrated framework that enables companies to monitor compliance, manage risks, and ensure governance practices are aligned with industry standards. By combining risk assessment, audit management, compliance tracking, and policy enforcement, these platforms empower businesses to strengthen decision-making and safeguard
Electronic Manufacturing Services (EMS) Market to Expand From $504.22 Billion in 2024 to $1,072.15 Billion by 2034 With 7.8% CAGR
Electronic Manufacturing Services (EMS) Market to Expand From $504.22 Billion in …
The Electronic Manufacturing Services (EMS) Market has become one of the most crucial sectors in the global technology-driven economy. EMS refers to the outsourcing of design, production, testing, and distribution of electronic components for original equipment manufacturers (OEMs). These services are indispensable across industries such as consumer electronics, automotive, telecommunications, and healthcare. In 2024, the EMS sector continues to play a pivotal role in improving efficiency, lowering production costs, and
Catamaran Market Is Anticipated To Expand From $4.2 Billion In 2024 To $7.8 Billion By 2034
Catamaran Market Is Anticipated To Expand From $4.2 Billion In 2024 To $7.8 Bill …
Market Overview The Catamaran Market is witnessing remarkable expansion, driven by the growing demand for recreational boating, marine tourism, and eco-friendly vessel options. Catamarans, recognized for their stability, spaciousness, and fuel efficiency, are increasingly preferred for leisure sailing, luxury tourism, and competitive racing. The market includes a wide range of offerings such as sailing catamarans, power catamarans, luxury yachts, and charter vessels, each catering to unique consumer preferences. Innovations in sustainable
Gear Motor Market to Expand From $24.5 Billion in 2024 to $39.8 Billion by 2034 With 5% CAGR
Gear Motor Market to Expand From $24.5 Billion in 2024 to $39.8 Billion by 2034 …
The gear motor market is witnessing steady growth as industries worldwide increasingly depend on reliable and energy-efficient motion control systems. Gear motors, which combine a motor with a gearbox, play a vital role in converting electrical energy into mechanical torque with higher efficiency. These systems are essential across sectors like automotive, robotics, manufacturing, and renewable energy, offering enhanced precision, power transmission, and performance. The market is strongly supported by the

All 5 Releases


More Releases for Benign

Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs …
The Drugs For Benign Prostatic hypertrophy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Drugs For Benign Prostatic hypertrophy Market? The drugs for benign prostatic hypertrophy market has shown strong growth, expanding from $4.28 billion in 2024 to $4.58
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be? In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be? In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.